In the STEP trials, semaglutide 2.4mg weekly resulted in mean weight reductions of 1517% over 68 weeks, whilst tirzepatide in the SURPASS trials showed reductions of 1520% (Kushner et al
Depending on the patient, a doctor may monitor A1C, fasting glucose, insulin resistance risk, cholesterol, triglycerides, liver enzymes, kidney function, blood pressure, inflammatory markers, thyroid status, and nutrient markers
In the context of lean mass preservation, future research should integrate more precise and clinically meaningful measures of muscle health, including muscle composition, mobility, and strength, rather than relying solely on body composition changes
Logan, a 28-year-old teacher from Iowa, told Hunterbrook Media he had been denied access to GLP-1 drugs by insurance four times even though he had been prescribed Wegovy by a doctor